title: Multicenter prospective study of sublobar resection for c-stage I non-small cell lung cancer patients unable to undergo lobectomy (KLSG-0801): complete republication.
abstract: BACKGROUND
  Local therapy for stage I non-small cell lung cancer (NSCLC) is divided into surgical and radiation treatment, and given to patients unable to tolerate a lobectomy. A prospective phase II study of cases that received stereotactic body radio therapy (SBRT) (JCOG0403) revealed an overall 3-year survival rate (3-YSR) of 76.0 %, 3-year relapse free survival rate (3-YRFS) of 69.0 %, and rate of morbidity of grade 3 or greater of 9 %. However, few prospective multicenter studies have reported regarding surgery for high-risk stage I NSCLC patients.
  
  
  METHODS
  We investigated this issue in the setting of a prospective multicenter observational study. Thirty-two high-risk NSCLC patients (30 males, 2 females; median age 74 years, 61-85 years) were analyzed.
  
  
  RESULTS
  Two (6.3 %) showed morbidity of grade 3 or greater, though there were no postoperative deaths. The margin local control rate was 97.0 % (surgical margin recurrence, 1) and local recurrence control rate was 75.0 % (ipsilateral thorax recurrence, 8), while the 3-YSR and 3-YRFS was 79.0 and 75.9 %, respectively.
  
  
  CONCLUSIONS
  A sublobar pulmonary resection for patients unable to tolerate a lobectomy with stage I NSCLC was shown to be safe and provided results comparable with those of SBRT.
authors.affiliation: General Thoracic Surgery, Saitama Cardiovascular and Respiratory Center, Kumagaya, Saitama, Japan.
authors.forename: Nobumasa
authors.initials: N
authors.lastname: Takahashi
authors.affiliation: Division of General Thoracic Surgery, Hoshigaoka Medical Center, Japan Community Healthcare Organization (JCHO), Hirakata, Osaka, 578-5811, Japan. nsawabata@hotmail.com.|Division of Health Care, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. nsawabata@hotmail.com.
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Sawabata
authors.affiliation: Division of Surgery, Teikyo University School of Medicine, Itabashi, Tokyo, Japan.
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kawamura
authors.affiliation: General Thoracic Surgery, Keio University, Shinjyuku, Tokyo, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Ohtsuka
authors.affiliation: General Thoracic Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyou, Tokyo, Japan.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Horio
authors.affiliation: General Thoracic Surgery, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
authors.forename: Hirozou
authors.initials: H
authors.lastname: Sakaguchi
authors.affiliation: General Thoracic Surgery, Saitama Medical University Saitama Medical Center, Kawagoe, Saitama, Japan.
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Nakayama
authors.affiliation: General Thoracic Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
authors.forename: Katsuo
authors.initials: K
authors.lastname: Yoshiya
authors.affiliation: General Thoracic Surgery, Dokkyo Medical University, Tokyo, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Chida
authors.affiliation: General Thoracic Surgery, Saitama Cardiovascular and Respiratory Center, Kumagaya, Saitama, Japan.
authors.forename: Eishin
authors.initials: E
authors.lastname: Hoshi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000601:surgery*; D000075202:Contraindications; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011013:Pneumonectomy / Q000009:adverse effects / Q000379:methods*; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
keywords: Conservative limited pulmonary resection; Non-small cell lung cancer; Prospective study; Stage I